Diet for Hypoglycemia

Hypoglycemia Diet News

Type 2 Diabetes Patients With Long-Standing Disease Achieved Glycemic Control When BYETTA(R) Was Added To Lantus(R)Saturday, July 10, 2010 @ 6:28AMAmylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) announced results from the first double-blind, placebo-controlled clinical study to evaluate BYETTA® (exenatide) injection added to Lantus® (insulin glargine), which showed patients with type 2 diabetes achieved glucose targets without weight gain or increasing their risk of hypoglycemia. These findings were ...

Tour de France Stage 4: Get over it to get to the AlpsFriday, July 9, 2010 @ 4:37PMGet over it is often tough-love advice to a person whining about something perceived as petty.

On Nutrition: Conversation about diabetesTuesday, July 6, 2010 @ 9:07PMControlling type 1 diabetes like "fencing in the fog"

Hope for people with type 2 diabetesTuesday, June 1, 2010 @ 3:43PMRick Gallop published his first book on the G.I. diet (Glycemic Index Diet) in 2002. He followed that one up with several others, but his most recent book makes a big claim. It's called The G.I. Diet Diabetes Clinic: A Week-by-Week Guide to Reversing Diabetes (Random House, $24.95).

The Lancet Publishes New Data Demonstrating Superior Efficacy Of Victoza(R) (liraglutide [rDNA] Injection) Compared To ...Saturday, April 24, 2010 @ 6:44AMYesterday, The Lancet published online the results of the first study comparing the once-daily human GLP-1 analog, Victoza® (liraglutide [rDNA] injection) with a DPP-4 inhibitor, Januvia®. The 26-week trial showed that Victoza® produced significantly greater reductions in A1C, fasting plasma glucose (FPG), and body weight than Januvia®, with similar or better overall treatment satisfaction...

AFREZZA Inhalation Powder reduces incidence of hypoglycemia in patients with Type 1 diabetesSaturday, April 24, 2010 @ 3:51AMDiabetes treatment regimens containing AFREZZATM (insulin human [rDNA origin]) Inhalation Powder, a well-tolerated, ultra rapid acting insulin, provide glucose control similar to standard insulin therapy along with weight loss and reduced incidence of hypoglycemia in patients with Type 1 diabetes and poorly controlled blood sugar levels, according to a two-year study presented today at the ...

The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to ...Friday, April 23, 2010 @ 11:10AMPRINCETON, N.J., April 23 /PRNewswire-FirstCall/ -- Yesterday, The Lancet published online the results of the first study comparing the once-daily human GLP-1 analog, Victoza® (liraglutide [rDNA] injection) with a DPP-4 inhibitor, Januvia®.

New Data Demonstrate Welchol(R) (colesevelam HCl) Significantly Improved Lipid and Glycemic Measures in Patients With ...Friday, April 23, 2010 @ 8:45AMResults of a new study showed that Welchol® 3.75 g/d significantly improved lipid and glycemic measures in patients with high LDL cholesterol and prediabetes .  The randomized, placebo-controlled, double-blind study was presented today at the American Association of Clinical Endocrinologists 19th Annual Meeting and Clinical Congress in Boston.  These data are consistent with previous studies ...

The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to ...Friday, April 23, 2010 @ 7:14AMPRINCETON, NJ--(Marketwire - April 23, 2010) - Yesterday, The Lancet published online the results of the first study comparing the once-daily human GLP-1 analog, Victoza ® (liraglutide [rDNA] injection) with a DPP-4 inhibitor, Januvia ® . The 26-week trial showed that Victoza ® produced significantly greater reductions in A1C, fasting plasma glucose (FPG), and body weight than Januvia ® , with ...